Novo Nordisk ( NVO -2.98%) stock is in a funk. Shares of the GLP-1 diet drug manufacturer have been sliding all week long, ...

In the GLP-1 weight loss market, it's largely been a two-horse race between Eli Lilly and Novo Nordisk (NYSE: NVO). The two companies have approved weight loss drugs that are generating billions in ...

The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower ...

Novo Nordisk will also succeed in decreasing its exposure to those markets in the next five years. In the meantime, the ...

Telehealth company Hims & Hers stirred up controversy by debuting a 2025 Super Bowl ad touting the benefits of its ...

Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.

NVO's fourth-quarter revenues are expected to have been driven by its sales of diabetes and obesity care products, especially ...

Danish drugmaker Novo Nordisk reported fourth quarter and full year 2024 earnings Wednesday, beating Wall Street's ...

Shares of Novo Nordisk ( NVO -3.62%) were moving higher on Wednesday. The company's stock gained 4.9% as of 1:50 p.m. ET, but ...

CEO Jan Mikkelsen highlighted 2024 as a pivotal year, with SKYTROFA achieving €200 million in revenue and a 6.5% share of the U.S. growth hormone market. The product now holds 45% of the U.S.

Novo Nordisk (NVO), a pharmaceutical company, isn’t too worried about the U.S. government’s plan to negotiate prices for its ...

Looking at options history for Novo Nordisk NVO we detected 8 trades. If we consider the specifics of each trade, it is ...